KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Equity Average (2016 - 2026)

NovoCure's Equity Average history spans 12 years, with the latest figure at $335.6 million for Q1 2026.

  • On a quarterly basis, Equity Average fell 7.06% to $335.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $335.6 million, a 7.06% decrease, with the full-year FY2025 number at $350.3 million, down 3.05% from a year prior.
  • Equity Average hit $335.6 million in Q1 2026 for NovoCure, down from $340.9 million in the prior quarter.
  • Over the last five years, Equity Average for NVCR hit a ceiling of $443.5 million in Q3 2022 and a floor of $335.6 million in Q1 2026.
  • Historically, Equity Average has averaged $386.7 million across 5 years, with a median of $361.3 million in 2024.
  • Biggest five-year swings in Equity Average: rose 14.06% in 2022 and later dropped 17.34% in 2024.
  • Tracing NVCR's Equity Average over 5 years: stood at $443.3 million in 2022, then dropped by 14.71% to $378.1 million in 2023, then decreased by 4.66% to $360.5 million in 2024, then dropped by 5.43% to $340.9 million in 2025, then fell by 1.56% to $335.6 million in 2026.
  • Business Quant data shows Equity Average for NVCR at $335.6 million in Q1 2026, $340.9 million in Q4 2025, and $345.4 million in Q3 2025.